Barinthus Biotherapeutics's quarterly market cap
declined
from Sep. 2025 (€42.46 Mil) to Dec. 2025 (€23.28 Mil) and
declined
from Dec. 2025 (€23.28 Mil) to Mar. 2026 (€19.20 Mil).
Barinthus Biotherapeutics's annual market cap
declined
from Dec. 2023 (€121.34 Mil) to Dec. 2024 (€39.23 Mil) and
declined
from Dec. 2024 (€39.23 Mil) to Dec. 2025 (€23.28 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Barinthus Biotherapeutics's Enterprise Value for Today is €-24.23 Mil.
Barinthus Biotherapeutics (STU:2AB) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Barinthus Biotherapeutics Market Cap Related Terms
Barinthus Biotherapeutics Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:2AB vs VTGN, PSTV, PVCT: Market Cap Comparison
For the Biotechnology subindustry, Barinthus Biotherapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Barinthus Biotherapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Barinthus Biotherapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Barinthus Biotherapeutics (STU:2AB) has a Market Cap of €23.08 Mil as of Jul. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Barinthus Biotherapeutics and its competitors. According to the industry distribution chart, Barinthus Biotherapeutics ranks #1037 out of 1427 companies in the Biotechnology industry, placing it in the top 72.7%.
Is Barinthus Biotherapeutics' Market Cap too high?
Barinthus Biotherapeutics' current Market Cap is €23.08 Mil. Based on the distribution chart, Barinthus Biotherapeutics ranks #1037 out of 1427 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Barinthus Biotherapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Barinthus Biotherapeutics' Market Cap compare to VTGN and PSTV?
According to the Biotechnology industry distribution chart, Barinthus Biotherapeutics ranks #1037 out of 1427 companies for Market Cap. This places Barinthus Biotherapeutics in the lower half of its industry. The industry median Market Cap is 119.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.57, based on 1,427 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Barinthus Biotherapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 119.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Barinthus Biotherapeutics's current Market Cap is €23.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Barinthus Biotherapeutics stock overvalued right now?
Barinthus Biotherapeutics (STU:2AB) has a current Market Cap of €23.08 Mil. The stock's GF Value™ is €0.94, compared to a current price of €0.57 — trading 39.9% below its estimated fair value. The current Market Cap is €23.08 Mil. Barinthus Biotherapeutics' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Barinthus Biotherapeutics (STU:2AB), the current Market Cap is €23.08 Mil as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Barinthus Biotherapeutics (STU:2AB) Overvalued in 2026?
Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued.
The current stock price of €0.57 is trading 39.9% below its estimated GF Value™ of €0.94.
Key valuation signals for STU:2AB:
Market Cap: €23.08 Mil
GF Value™: €0.94 vs. price of €0.57 (39.9% below fair value)
No single metric tells the full story. See the STU:2AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
14GF Score
Get the complete analysis for STU:2AB
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2AB has been successfully added to your 
